Yeah, it would have been nice though if they'd gotten their facts straight:
During this year’s Bloom Burton & Co. Healthcare Investment Conference in Toronto, Don McCaffrey, CEO of Resverlogix (TSX:RVX) gave INN an update on the company as it, at the time, prepared for a phase 3 clinical trial for its candidate.
“[It’s] very rare that a small biotech company can complete a Phase 3 cardiovascular trial on their own,” McCaffrey explained.
Uhm really? Prepared for, as in getting read for? It wasn't being prepared, it was on-going.
